Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

por Dedic, Nina, Dworak, Heather, Zeni, Courtney, Rutigliano, Grazia, Howes, Oliver D.
Publicado 2021

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D(2)-Based Pharmacological Class Effect Query Defined by FAERS

por Hopkins, Seth C., Ogirala, Ajay, Zeni, Courtney, Worden, MaryAlice, Koblan, Kenneth S.
Publicado 2022

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia

por Achtyes, Eric D., Hopkins, Seth C., Dedic, Nina, Dworak, Heather, Zeni, Courtney, Koblan, Kenneth
Publicado 2023